HIGHLIGHTS
- who: Chao Zhang from the Published in partnership with The Hormel Institute, University of Minnesota have published the article: Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis, in the Journal: (JOURNAL) of 23/01/2022
- what: Owing to its retrospective nature, this study had two primary limitations of this study.
- how: Inter-tumoral heterogeneity of immune contexture between PL and DLNs might reveal diverse response to neoadjuvant immunotherapy To further illustrate why localized oncogene-mutant NSCLC might be responsive or ineffective to immunotherapy the authors investigated the inter . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.